The Different Response of Endocrine Hormones to Hypoglycemia in Patients With Type 1 or Type 2 Diabetes
NCT ID: NCT05290207
Last Updated: 2023-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
35 participants
OBSERVATIONAL
2022-01-06
2022-09-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine
NCT03566472
Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors
NCT00607139
Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects
NCT02574793
Investigation Into the Effects Upon Brain Response to Change in Circulating Glucose Levels in Diabetes Mellitus
NCT00580710
A Study to Learn How Well a Monitoring System Called Continuous Glucose Monitoring (CGM) Which Measures Glucose on an Ongoing Basis Works and How Safe it is in Chinese Patients in Usual Practice
NCT05038761
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Newly diagnosed male obese patients with type 2 diabetes
The hyperinsulinaemic hypoglycaemic clamp
Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
Newly diagnosed male non-obese patients with type 2 diabetes
The hyperinsulinaemic hypoglycaemic clamp
Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
Newly diagnosed male patients with type 1 diabetes
The hyperinsulinaemic hypoglycaemic clamp
Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
Healthy, non-obese men
The hyperinsulinaemic hypoglycaemic clamp
Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The hyperinsulinaemic hypoglycaemic clamp
Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* newly diagnosed male patients with type 1 or type 2 diabetes (diagnostic criteria of World Health Organization)
* aged 18-50 years
* has not been treated with any hypoglycemic drugs
* HbA1c\>9% Normal subjects: healthy and had no known illness
Exclusion Criteria
* any history of hypoglycemic agent intake or were presently taking hypoglycemic agents
* any abnormality in liver or kidney function on blood and urine investigations
* any history of systemic corticosteroid use in 3 months
* any recent infections or acute medical events
* any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing First Hospital, Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jian-hua Ma
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanjing First Hospital, Nanjing Medical Univesity
Nanjing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20220124-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.